NEW YORK, May 27, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980.
The investigation concerns whether Jazz and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 27, 2016, Bloomberg reported that Jazz had received a subpoena from the U.S. Attorney for the District of Massachusetts, initially disclosed on May 10, 2016 in the Company's 10-Q for the quarter ended March 31, 2016, seeking documents related to the Company's relationship with certain nonprofits that provide financial assistance to patients. The Bloomberg article described how Jazz and other pharmaceutical companies make large contributions to copay charities that help patients afford their products.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jazz-pharmaceuticals-plc--jazz-300276235.html
SOURCE Pomerantz LLP